Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

AQST
Aquestive Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open
May 19, 2025 12:58:12 PM EDT
2.38USD+0.210%(0.00)1,269,775
2.38Bid   2.39Ask   0.01Spread
Pre-market
May 19, 2025 8:41:30 AM EDT
2.35USD-1.261%(-0.03)1,100
After-hours
May 16, 2025 4:58:30 PM EDT
2.37USD-0.837%(-0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 13, 2022
11:50AM EST  Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST) breached their fiduciary duties of loyalty, good faith and candor and whether the Company suffered substantial harm as a result.   GlobeNewswire Inc
Jan 7, 2022
08:00AM EST  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th.   GlobeNewswire Inc
Dec 22, 2021
04:45PM EST  16:45 Wednesday, December 22, 2021Wedbush (RTTNews) - Wedbush Reiterates Aquestive Therapeutics Inc. (AQST) At Outperform With $26 Down From $28 Price Target   RTTNews
Dec 21, 2021
08:12AM EST  The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail   Benzinga
05:27AM EST  Aquestive Therapeutics Announced it Received Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company's NDA for Libervant Buccal Film   Benzinga
Dec 20, 2021
10:49PM EST  Aquestive Therapeutics Receives Notification from FDA that It Will   GlobeNewswire Inc
Dec 19, 2021
12:54PM EST  The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week   Benzinga
Dec 17, 2021
08:06AM EST  Aquestive Therapeutics Added To NASDAQ Biotechnology Index Effective Dec. 20, 2021   Benzinga
08:00AM EST  Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients unmet needs and solve therapeutic problems, today announced that NASDAQ has added the company to the NASDAQ Biotechnology Index (Nasdaq: NBI) effective December 20, 2021.   GlobeNewswire Inc
Dec 13, 2021
08:07AM EST  Aquestive Therapeutics Receives Written Response To Pre-IND Submission For AQST-109 And Begins Recruitment For Epinephrine Film Pharmacokinetic And Safety Trial; FDA Confirms 505(b)(2) Pathway Is Acceptable   Benzinga
08:00AM EST  -- FDA confirms 505(b)(2) pathway is acceptable for the development of AQST-109 -- FDA indicates AQST-109 has the potential for Fast Track designation -- Health Canada provides clearance to commence the adaptive design crossover study   GlobeNewswire Inc
Dec 7, 2021
07:28AM EST  Aquestive Therapeutics Granted U.S. Patent #11,191,737 'Enhanced delivery epinephrine compositions'   Benzinga
Dec 2, 2021
12:02PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Nov 29, 2021
08:30AM EST  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET.   GlobeNewswire Inc
Nov 17, 2021
08:00AM EST  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd.   GlobeNewswire Inc
Nov 2, 2021
05:45PM EDT  Aquestive Therapeutics Sees FY21 Revs $47M-$49M Vs $48.32M Est   Benzinga
05:43PM EDT  Aquestive Therapeutics Q3 EPS $(0.37) Beats $(0.45) Estimate, Sales $13.29M Beat $11.01M Estimate   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
Oct 25, 2021
08:58AM EDT  Aquestive Reports Positive Data From Phase 1 Trial Of AQST-109 On Emergency Treatment Of Allergic Reactions   RTTNews
08:39AM EDT  Aquestive Therapeutics Reports Positive Topline Data From First-in-human Phase 1 PK Study Of AQST-109 Sublingual Film   RTTNews
08:33AM EDT  Aquestive Therapeutics Reports Positive Topline Data From Phase 1 Pharmacokinetic Trial Of AQST-109 Supporting Its Development As Oral Alternative To Epinephrine Autoinjectors For Emergency Treatment Of Allergic Reactions   Benzinga
08:31AM EDT  Aquestive Therapeutics Reports Positive Topline Data from Phase 1   GlobeNewswire Inc
Oct 14, 2021
08:00AM EDT  Aquestive Therapeutics to Report Third Quarter 2021 Financial   GlobeNewswire Inc
Oct 6, 2021
05:59PM EDT  Aquestive Therapeutics Reaches Agreement to Extend Principal   GlobeNewswire Inc
Sep 29, 2021
04:31PM EDT  IntelGenx And Aquestive Therapeutics Partner With Leading Men's Health Company To Market Tadalafil Oral Films In The U.S.   Benzinga
04:30PM EDT  IntelGenx and Aquestive Therapeutics Partner with Leading   GlobeNewswire Inc
Sep 7, 2021
08:00AM EDT  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that the management team will participate in three upcoming investor conferences in September as follows:   GlobeNewswire Inc
Aug 30, 2021
11:32AM EDT  Aquestive Therapeutics Option Alert: Feb 18 $5 Calls Sweep (35) near the Ask: 299 @ $1.601 vs 482 OI; Ref=$4.68   Benzinga
Aug 20, 2021
01:50PM EDT  Looking into Aquestive Therapeutics's Return on Capital Employed   Benzinga
Aug 9, 2021
08:06AM EDT  Aquestive Therapeutics Extends the Term on its Credit Facility by 6 Months   Benzinga
08:00AM EDT  -- Provides access to $30 million in capital contingent on FDA approval and U.S. market access for Libervant   GlobeNewswire Inc
Aug 6, 2021
08:00AM EDT  Aquestive Therapeutics to Participate in 12th Annual Wedbush   GlobeNewswire Inc
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
06:06PM EDT  Aquestive Therapeutics Q2 EPS $(0.33) Beats $(0.44) Estimate, Sales $15.30M Beat $9.48M Estimate   Benzinga
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Jul 21, 2021
08:00AM EDT  Aquestive Therapeutics to Report Second Quarter 2021 Financial   GlobeNewswire Inc
Jul 19, 2021
09:30AM EDT  Aquestive Therapeutics Announces FDA Acceptance Of New Drug Application Resubmission For Libervant Buccal Film   Benzinga
09:30AM EDT  -- Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021 -- If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters   GlobeNewswire Inc
Jun 24, 2021
08:13AM EDT  UPDATE: Aquestive Sees PDUFA Goal Date for Libervant Late 2021   Benzinga
08:13AM EDT  Aquestive Therapeutics Reports Resubmission Of New Drug Application For Libervant Buccal Film   Benzinga
08:00AM EDT  -- Anticipates FDA PDUFA goal date in late 2021 -- If approved by the FDA for US market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters   GlobeNewswire Inc
Jun 23, 2021
08:30AM EDT  -- BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 years -- Commercial launch update call is scheduled for Tuesday, June 29th @ 12pm ET   GlobeNewswire Inc
Jun 21, 2021
09:16AM EDT  Aquestive Therapeutics Announces Leadership Transition of Chief   GlobeNewswire Inc
Jun 9, 2021
08:30AM EDT  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that the management team will participate in two upcoming investor conferences in June.   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
09:28AM EDT  Aquestive Therapeutics to Participate in 2021 RBC Capital Markets   GlobeNewswire Inc
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 24, 2021
12:31AM EDT  Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ:AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Apr 21, 2021
09:19AM EDT  Aquestive Therapeutics to Report First Quarter 2021 Financial   GlobeNewswire Inc
Apr 14, 2021
11:04PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ:AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Mar 25, 2021
08:41AM EDT  Aquestive Therapeutics To Provide Clinical Data At Today's R&D Event   Benzinga
08:30AM EDT  -- Provides in-depth scientific and clinical data in R&D event today at 9:00 am ET -- Outlines data from two completed Phase 1 pharmacokinetic (PK) trials for AQST-108 (dipivefrin) sublingual film -- Articulates development strategy for second prodrug candidate, AQST-109 sublingual film -- Provides details on potential patent coverage to at least 2037   GlobeNewswire Inc
Mar 9, 2021
05:54PM EST  Aquestive Therapeutics Sees Total Revs. $38M-$42M Vs $41.19M Est.; Sees Non-GAAP Adj. EBITDA Loss Of ~$42M-$45M   Benzinga
05:50PM EST  Aquestive Therapeutics Q4 EPS $(0.60) Misses $(0.26) Estimate, Sales $7.15M Beat $6.25M Estimate   Benzinga
05:49PM EST  Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020   GlobeNewswire Inc
09:17AM EST  The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data   Benzinga
04:09AM EST  Earnings Scheduled For March 9, 2021   Benzinga
Mar 8, 2021
10:08AM EST  Aquestive Therapeutics Earnings Preview   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 5, 2021
12:07PM EST  Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) from December 2, 2019 through September 25, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Aquestive Therapeutics, Inc. investors under the federal securities laws.   GlobeNewswire Inc
07:13AM EST  Aquestive Therapeutics To Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event On March 25 t 9:00 a.m. ET   Benzinga
07:00AM EST  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that it will host a virtual investor and analyst epinephrine drug delivery research and development event on Thursday, March 25, 2021 at 9:00 am ET.   GlobeNewswire Inc
Mar 3, 2021
10:16AM EST  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has   GlobeNewswire Inc
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 2, 2021
04:03PM EST  AQST INVESTOR ALERT: Bernstein Liebhard LLP Announces that a   GlobeNewswire Inc
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
Mar 1, 2021
11:28PM EST  Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive   PR Newswire
Feb 28, 2021
11:38AM EST  Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 25, 2021
11:07AM EST  Aquestive Sees Libervant Application Resubmission By End Of Q2   Benzinga
08:04AM EST  Aquestive Therapeutics Says Received Additional Feedback From FDA After Completion Of Type A Meeting And Submission; Anticipates FDA Action Date In 2021   Benzinga
07:30AM EST  -- Reaffirms plans to resubmit its New Drug Application (NDA) around the end of second quarter 2021 -- Received additional feedback from FDA after completion of Type A meeting and submission of revised weight based dosing regimen -- Anticipates an FDA action date in 2021   GlobeNewswire Inc
Feb 17, 2021
07:30AM EST  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that it will report results for the fourth quarter and year ended December 31, 2020 and provide a business update after market close on Tuesday, March 9, 2021.   GlobeNewswire Inc
Feb 9, 2021
07:44AM EST  Aquestive Adds Julie Krop, Marco Taglietti To Board; Douglas Bratton Resigns From Board   RTTNews
07:30AM EST  Aquestive Therapeutics Strengthens Board of Directors with   GlobeNewswire Inc
Jan 28, 2021
07:30AM EST  -- New hire helps lead Aquestives continued focus on its epinephrine program -- Provides update on Libervant (diazepam) Buccal Film   GlobeNewswire Inc
Jan 21, 2021
08:40AM EST  Mitsubishi And Aquestive Announce U.S. Licensing And Supply Deal For Riluzole Oral Film For ALS Treatment   RTTNews
08:33AM EST  Mitsubishi Tanabe Pharma America, Aquestive Therapeutics Announce U.S. Licensing And Supply Deal For Riluzole Oral Film For ALS Treatment   Benzinga
08:31AM EST  Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S.   PR Newswire
Jan 7, 2021
07:37AM EST  Aquestive Therapeutics Announces Resubmitted Revised Dosing Regimen For Libervant To Fda In December 2020, As Committed   Benzinga
07:30AM EST  -- Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committed -- Multiple clinical trials demonstrate that AQST-108 can consistently deliver epinephrine   GlobeNewswire Inc
Jan 4, 2021
07:30AM EST  Aquestive Therapeutics to Present at Two Upcoming Investor Conferences   GlobeNewswire Inc
Dec 16, 2020
08:03AM EST  Aquestive Therapeutics Announces Departure Of CFO John Maxwell, Ernie Toth To Assume Interim CFO Role Upon Maxwell's Departure   Benzinga
08:03AM EST  Aquestive Therapeutics Announces Departure Of CFO John Maxwell, Ernie Toth To Assume CFO Role Upon Maxwell's Departure   Benzinga
08:00AM EST  Aquestive Therapeutics Announces Departure of Chief Financial   GlobeNewswire Inc
Nov 25, 2020
09:15AM EST  Aquestive Therapeutics to Present at Piper Sandler 32nd Annual   GlobeNewswire Inc
Nov 23, 2020
07:15AM EST  Aquestive Therapeutics Receives $10M Milestone Payment Under Royalty Monetization Agreement With An Affiliate Of Marathon Asset Management   Benzinga
07:14AM EST  Aqestive Therapeutics Receives $10M in a Milestone Payment From Marathon Asset Management   Benzinga
07:00AM EST  Aquestive Therapeutics Receives First Milestone Payment from   GlobeNewswire Inc
Nov 19, 2020
03:18PM EST  Why Aquestive Therapeutics Stock Is Trading Higher Today   Benzinga
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
Nov 18, 2020
06:18PM EST  After-Hours Market: Nuance, Sonos, Aquestive, Lantheus   RTTNews
04:02PM EST  Aquestive Therapeutics Completes FDA Type A Meeting On Libervant; FDA Confirms Issues Identified In CRL Of September 25, 2020 May Be Addressed By Utilizing Modeling And Simulations For An Updated Dosing Regimen   Benzinga
04:01PM EST  -- FDA confirms issues identified in FDA Complete Response Letter (CRL) of September 25, 2020 may be addressed by utilizing modeling and simulations for an updated dosing regimen -- FDA recommends and Aquestive agrees to a follow-up FDA meeting prior to resubmission   GlobeNewswire Inc
Nov 4, 2020
05:02PM EST  Acquestive Therapeutics Sees FY2020 Revenue Between $42M And $46M, Adjusted EBITDA Loss Between $38M And $42M   Benzinga
05:01PM EST  Aquestive Therapeutics Q3 EPS $(0.49) Misses $(0.46) Estimate, Sales $8.30M Miss $8.72M Estimate   Benzinga
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
04:41AM EST  Earnings Scheduled For November 4, 2020   Benzinga
Nov 3, 2020
07:01AM EST  Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125M   Benzinga
07:00AM EST  -- Receives $40 million of proceedsat closing, with potential $25 million of additional proceeds by mid-2022 -- Reduces outstanding debt to $51.5 million   GlobeNewswire Inc
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 14, 2020
07:30AM EDT  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that it will report results for the third quarter ended September 30, 2020 and provide a business update after market close on Wednesday, November 4, 2020.   GlobeNewswire Inc
Sep 28, 2020
02:35PM EDT  Mid-Afternoon Market Update: Dow Surges 500 Points; Piedmont Lithium Shares Spike Higher   Benzinga
12:10PM EDT  Mid-Day Market Update: Perceptron Jumps Following Acquisition News; Inovio Pharmaceuticals Shares Plunge   Benzinga
10:10AM EDT  Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Reports Narrower-Than-Expected Loss   Benzinga
07:32AM EDT  RBC Capital Maintains Outperform on Aquestive Therapeutics, Lowers Price Target to $7   Benzinga
07:30AM EDT  Aquestive Therapeutics Late Friday Received A Complete Response Letter From FDA For Libervant Buccal Film Indicating The Application Cannot Be Approved In Its Current Form; Letter 'cites exposure levels (Cmax) in certain weight groups'   Benzinga
07:01AM EDT  HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Lowers Price Target to $14   Benzinga
06:53AM EDT  Aquestive Therapeutics Late Friday Receives Complete Response Letter from FDA for Libervant Buccal Film for Management of Seizure Clusters   Benzinga
Sep 25, 2020
05:38PM EDT  -- Complete Response Letter cites exposure levels (Cmax) in certain weight groups -- No additional clinical studies anticipated by Aquestive -- No Clinical Safety issues or Non-Clinical Chemistry, Manufacturing and Controls (CMC) issues identified -- Conference call and webcast today at 6:30 p.m. ET   GlobeNewswire Inc
Aug 20, 2020
07:37AM EDT  Aquestive Therapeutics Initiates Phase 1 Pharacokinetic Trial Of AQST-108 In Development For Treatment Of Allergic Reactions Including Anaphylaxis   Benzinga
07:36AM EDT  Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial Of AQST-108 For Allergic Reactions Incl Anaphylaxis   RTTNews
07:30AM EDT  -- First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxis -- Pharmacokinetic and pharmacodynamics data expected in fourth quarter 2020   GlobeNewswire Inc
Aug 10, 2020
07:42AM EDT  Aquestive Therapeutics Receives FDA Fast Track Designation For AQST-108 For Treatment Of Allergic Reactions Including Anaphylaxis   Benzinga
07:42AM EDT  -- Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 -- First planned PK clinical trial expected to begin during the third quarter of 2020   GlobeNewswire Inc
Aug 4, 2020
04:25PM EDT  Aquestive Therapeutics Q2 EPS $(0.07) Up From $(0.82) YoY, Sales $21.68M Up From $11.13M YoY   Benzinga
04:01PM EDT  Aquestive Therapeutics Reports Second Quarter 2020 Financial   GlobeNewswire Inc
05:19AM EDT  Earnings Scheduled For August 4, 2020   Benzinga
Jul 28, 2020
04:15PM EDT  Aquestive Therapeutics to Present at 2020 Wedbush PacGrow   GlobeNewswire Inc
Jul 15, 2020
07:58AM EDT  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that it will report results for the second quarter ended June 30, 2020 and provide a business update after market close on Tuesday, August 4, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC